GLP-1s: The Biggest Drug Breakthrough Ever
-
- Einzelkauf Download ausgewählt
-
Sprache:Englisch
0,99 €
inkl. gesetzl. MwSt.Beschreibung
Produktdetails
Format
ePUB
Kopierschutz
Ja
Family Sharing
Ja
Text-to-Speech
Ja
Erscheinungsdatum
09.05.2026
Verlag
The Turing AppSeitenzahl
(Printausgabe)
Dateigröße
1520 KB
Sprache
Englisch
EAN
9798235791398
This pocketbook is a complete essential guide to the medical, cultural, and economic revolution sparked by glucagon-like peptide-1 (GLP-1) drugs. Written in everyday language, we explore how medications once designed for diabetes became the most promising weight-loss tools in the world, and why their impact may extend far beyond obesity.
The book begins with the long history of failed diet promises, from crash diets and stimulants to low-carb fads and meal-replacement plans. It then explains why glucagon-like peptide-1 (GLP-1) receptor agonists are different. Rather than relying on willpower or stimulants, these drugs mimic a natural gut hormone that helps regulate blood sugar, slow digestion, increase fullness, and reduce appetite through the body's own metabolic signaling system.
The book also explores the enormous disruption created by these drugs. We explore how Ozempic, Wegovy, Mounjaro, and related treatments have transformed the pharmaceutical industry, overwhelmed supply chains, reshaped telemedicine, and forced traditional weight-loss companies, gyms, food brands, clothing retailers, cosmetic clinics, and even airlines to adapt. At the same time, there are controversies: high prices, insurance barriers, shortages for diabetic patients, side effects, long-term uncertainty, and the risk of weight regain after stopping treatment.
The book explains how glucagon-like peptide-1 (GLP-1) drugs may improve cardiovascular health, reduce inflammation, protect kidney and liver function, and possibly influence conditions tied to the brain, addiction, mood, and neurodegeneration. What began as a treatment for blood sugar has become a window into metabolism as a central driver of chronic disease.
Finally, the book ends with where this revolution goes next. We explore oral formulations, dual and triple agonists, generics, preventive medicine, longevity research, and the ethical question of who gets access if these drugs truly reshape the future of health. It ends with a clear tension: glucagon-like peptide-1 (GLP-1) drugs may become one of the great medical breakthroughs of our time, but only if science, safety, affordability, and fairness can keep pace with the hype.
Kundinnen und Kunden meinen
Verfassen Sie die erste Bewertung zu diesem Artikel
Helfen Sie anderen Kund*innen durch Ihre Meinung
Kurze Frage zu unserer Seite
Vielen Dank für Ihr Feedback
Wir nutzen Ihr Feedback, um unsere Produktseiten zu verbessern. Bitte haben Sie Verständnis, dass wir Ihnen keine Rückmeldung geben können. Falls Sie Kontakt mit uns aufnehmen möchten, können Sie sich aber gerne an unseren Kund*innenservice wenden.
zum Kundenservice